+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Methicillin-resistant Staphylococcus aureus Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

  • ID: 4517510
  • Report
  • 132 pages
  • Prescient & Strategic Intelligence Private Limited
1 of 2
MRSA infection caused by specific "staph" bacteria that is often resistant to most of antibiotic treatments. S. aureus (SA) is listed as a ‘superbug’ by U.S. Centers for Disease Control and Prevention (CDC). MRSA can either be present harmlessly on the skin (colonization) or enter the body (e.g. through broken skin) and cause an infection. The study analyzed that MRSA infection therapeutics pipeline comprises approximately 52 drug candidates in different stages of development.

Insights on Pipeline Segments

According to the research findings, a majority of the drug candidates for the treatment of MRSA are being developed to be administered by the intravenous route which offers good bioavailability and is considered to be more effective at the target site.

Pipeline Supported by Research Funding from Various Agencies

The players in the MRSA therapeutics pipeline have been receiving increasing support from various organizations in the form of research funding. For instance, Microbiotix Inc received Phase l grants from SBIR for “Inhibitors of wall teichoic acid biosynthesis of Staphylococcus aureus” for a term of two years in February 2012.

MRSA pipeline characterized by Drug candidates with Novel Mechanism of Action

It has been observed that most of the companies are developing drug candidates with novel mechanism of action. Also, the drug candidates have showed positive efficacy in the clinical as well as Pre-Clinical stage of development. For instance, GlaxoSmithKline plc is developing a Phase II drug candidate, GSK 2140944 or Gepotidacin. It is an intravenous, synthetic, Type II topoisomerase inhibitor. If GSK2140944 hits the market, it would be the first topoisomerase inhibitor for gram-negative infections. Savara Pharma's AeroVanc is the first inhaled antibiotic being developed and is in the Phase III stage of clinical trial and has received $5 million fund from Nonprofit Cystic Fibrosis Foundation. If the drug receives the approval, it would be the first inhaled antibiotic to be developed for the treatment of MRSA.

Some of the key players involved in the development of MRSA therapeutics include GlaxoSmithKline plc, Crystal Genomics Inc., and Innovation Pharmaceuticals Inc.
Note: Product cover images may vary from those shown
2 of 2
1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.3.1 Pipeline Analysis by Phase
1.3.2 Pipeline Analysis by Molecule Type
1.3.3 Pipeline Analysis by Route of Administration
1.4 Key Stakeholders

2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents by industry participant by company type

3. Executive Summary

4. Pipeline Outlook
4.1 Disease Overview
4.2 Causes
4.3 Symptoms
4.3.1 Complications
4.4 Diagnosis
4.5 Treatment
4.6 Prevention of MRSA infection
4.7 Epidemiology
4.8 Key Drivers
4.8.1 Research Funding from Various Agencies
4.8.2 Increasing number of Immune Compromised Population
4.9 Key Barriers
4.9.1 Growing Bacterial Resistance towards Various Antibiotics
4.10 MRSA Therapeutics Pipeline Analysis
4.10.1 Pipeline Analysis by Phase
4.10.2 Pipeline Analysis by Molecule Type
4.10.3 Pipeline Analysis by Route of Administration
4.10.4 Pipeline Analysis by Company

5. MRSA Infections Therapeutics Pipeline Analysis by Phase (2018)
5.1 Phase III
5.1.1 AeroVanc
5.1.2 X
5.1.3 X
5.1.4 X
5.2 Phase II
5.2.1 CG400549
5.2.2 X
5.2.3 X
5.2.4 X Clinical trials Clinical results
5.2.5 X
5.2.6 X
5.2.7 X
5.2.8 X
5.2.9 X
5.2.10 X
5.2.11 X
5.2.12 X
5.2.13 X
5.2.14 X
5.2.15 X
5.3 Phase I
5.3.1 AB-SA01 Clinical trials Strategic Development Patent
5.3.2 X Strategic Development Technology
5.3.3 X Strategic Development Technology
5.3.4 X
5.3.5 X Strategic Development
5.4 Pre-Clinical
5.4.1 Vaccines for MRSA Strategic development
5.4.2 X Patent
5.4.3 X Strategic development
5.4.4 X Strategic developments
5.4.5 X Strategic developments
5.4.6 X Strategic developments
5.4.7 X Strategic developments
5.4.8 X
5.4.9 X Strategic Development
5.4.10 X Strategic developments
5.4.11 X
5.4.12 X
5.4.13 X Pre-Clinical study
5.4.14 X Patents
5.4.15 X Patent
5.4.16 X
5.5 Discovery
5.5.1 AP 138
5.5.2 X
5.5.3 X Patents
5.5.4 X Patents
5.5.5 X Patents
5.5.6 X
5.5.7 X
5.5.8 X Strategic developments
5.5.9 X
5.6 Unknown
5.6.1 MP106
5.6.2 X Strategic Development
5.6.3 X

6. Clinical Trials Review
6.1 Clinical Trials by Region
6.2 Clinical Trials by Trial Status

7. Competitive Landscape
7.1 Key Players Benchmarking
7.2 SWOT Analysis
7.2.1 Strengths
7.2.2 Weaknesses
7.2.3 Opportunities
7.2.4 Threats

8. Company Profiles
8.1 GlaxoSmithKline PLC
8.1.1 Business Overview
8.1.2 Product & Service Offerings
8.2 X
8.2.1 Business Overview
8.2.2 Product & Service Offerings
8.3 X
8.3.1 Business Overview
8.3.2 Product & Service Offerings
8.4 X
8.4.1 Business Overview
8.4.2 Product & Service Offerings
8.5 X
8.5.1 Business Overview
8.5.2 Product & Service Offerings
8.6 X
8.6.1 Business Overview
8.6.2 Product & Service Offerings
8.7 X
8.7.1 Business Overview
8.7.2 Product & Service Offerings
8.8 X
8.8.1 Business Overview
8.8.2 Product & Service Offerings
8.9 X
8.9.1 Business Overview
8.9.2 Product & Service Offerings
8.10 X
8.10.1 Business Overview
8.10.2 Product & Service Offerings

9. Appendix
9.1 Abbreviations
9.2 Related Reports

List of Tables
Table 1 Pipeline Analysis of Mrsa Infections Therapeutics, by Company (2018)
Table 2 Description of Aerovanc
Table 3 Description of X
Table 4 Description of X
Table 5 Description of X
Table 6 Description of Cg400549
Table 7 Description of X
Table 8 Clinical Trials of X
Table 9 Description of X
Table 10 Clinical Trials of X
Table 11 Description of X
Table 12 Clinical Trials of X
Table 13 Description of X
Table 14 Description of X
Table 15 Description of X
Table 16 Description of X
Table 17 Description of X
Table 18 Description of X
Table 19 Description of X
Table 20 Description of X
Table 21 Description of X
Table 22 Description of X
Table 23 Description of X
Table 24 Description of Ab-Sa01
Table 25 Clinical Trials of Ab-Sa01
Table 26 Description of X
Table 27 Description of X
Table 28 Description of X
Table 29 Description of X
Table 30 Description of Vaccine For Mrsa
Table 31 Description of X
Table 32 Description of X
Table 33 Description of X
Table 34 Description of X
Table 35 Description of X
Table 36 Description of X
Table 37 Description of X
Table 38 Description of X
Table 39 Description of X
Table 40 Description of X
Table 41 Description of X
Table 42 Description of X
Table 43 Description of X
Table 44 Description of X
Table 45 Description of X
Table 46 Description of Ap 138
Table 47 Description of X
Table 48 Description of X
Table 49 Description of X
Table 50 Description of X
Table 51 Description of X
Table 52 Description of X
Table 53 Description of X
Table 54 Description of X
Table 55 Description of X
Table 56 Description of X
Table 57 Description of X
Table 58 Glaxosmithkline Plc - At a Glance
Table 59 X - At a Glance
Table 60 X - At a Glance
Table 61 X - At a Glance
Table 62 X - At a Glance
Table 63 X - At a Glance
Table 64 X - At a Glance
Table 65 X - At a Glance
Table 66 X - At a Glance
Table 67 X - At a Glance

List of Figures
Fig 1 Research Methodology
Fig 2 Breakdown of Primary Research Respondents, by Industry Participant
Fig 3 Breakdown of Primary Research Respondents, by Company Type
Fig 4 Mrsa Drug Candidates In Development (2018)
Fig 5 Mrsa Infections Pipeline Split, by Molecule Type (2018)
Fig 6 Mrsa Infections Pipeline Split, by Route of Administration (2018)
Fig 7 Breakdown of Clinical Trials, by Region
Fig 8 Breakdown of Clinical Trials, by Trial Status
Fig 9 Key Players Benchmarking
Fig 10 SWOT Analysis
Note: Product cover images may vary from those shown
3 of 2


Order Online - visit: https://www.researchandmarkets.com/reports/4517510